The startup specializes in the application of microbiota to enhance micro-ecological immunity through targeted nutritional interventions. Their research focuses on addressing diseases such as COVID-19, colorectal cancer, obesity, eczema, and autism by leveraging the therapeutic potential of gut microbiota.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including COVID-19, colorectal cancer, eczema, obesity, autism, and mood disorders, are associated with imbalances in the gut microbiota. Current therapeutic options often lack precision in restoring microbial balance and addressing the root causes of these conditions.
Solution
G-NiiB GenieBiome leverages a data-driven approach to develop microbiome-based therapeutics and diagnostics. The company utilizes advanced metagenomic sequencing and AI-driven analysis of a large Asian human microbial dataset to identify disease-specific microbial signatures. This platform enables the development of precision microbiome formulas and non-invasive diagnostic tests for early disease prevention, diagnosis, and treatment. G-NiiB's therapeutic platform focuses on creating novel microbial consortia with beneficial functional and metabolic profiles, while its diagnostic platform aims to identify proprietary microbial biomarkers for disease risk prediction.
Target Audience
The primary target audience includes individuals seeking preventative and therapeutic solutions for gut-related health issues, as well as healthcare providers looking for advanced diagnostic tools and precision microbiome interventions.
Features
- Comprehensive Asian human microbiome database with over 8,000 stool samples and extensive metadata
- AI-driven metagenomic sequencing for identifying disease-specific microbial signatures
- Development of precision microbiome formulas to restore gut microbial balance
- Non-invasive colorectal cancer risk prediction test (M3CRC) for detecting non-advanced adenoma and adenoma recurrence
- Patented precision microbiome formulas, including SIM01 for immunity, SMT04 for gut protection, and SIM03 for children's immunity
- Oral live microencapsulated bacteria for targeted delivery and enhanced efficacy
- PCR-based technologies for disease risk prediction
- Isolation of over 20 novel live bacteria strains with therapeutically active functions